ArticleCNS neuroscience & therapeutics2026
Developmental Deficiency of Oligodendrocytes and Myelination in the Central Nervous System of the Fetal Alcohol Syndrome Mouse Model.
Article in CNS neuroscience & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundFetal alcohol spectrum disorder (FASD) is a severe condition characterized by physical and neurodevelopmental abnormalities in the fetus resulting from prenatal alcohol exposure (PAE) or prenatal and lactation alcohol exposure (PLAE). Behavioral abnormalities associated with white matter damage have been extensively investigated in FASD patients and animal models, which suggested the involvement of myelination in FASD pathology. However, the impact of FASD on oligodendrocytes (OLs) and myelination within the central nervous system (CNS) and the underlying mechanisms are little discovered. This study aimed to reveal the effect and role of PLAE on CNS myelination in a FASD mouse model.
methodsWe set up a PLAE approach to generate the FASD mouse model to explore the effects of FASD on CNS myelination. Open-field test, elevated plus maze, and tail suspension test were used to evaluate possible behavior deficiency of the FASD mice. Myelination in the cortex and hippocampus of the FASD mice was detected at postnatal days 14, 21, and 90 (P14, P21, and P 90). Then we counted the number of oligodendrocyte precursor cells (OPCs) and mature oligodendrocytes (mOLs) to reveal the cell fates of oligodendrocyte lineage cells in the FASD mice. Next, we set up BLBP+/GFAP+ double-staining to monitor the possible dysfunction of radial glial cells, which may contribute to the myelination deficiency in FASD mice. Finally, an FDA-approved pro-myelination drug, clemastine fumarate (CF), was used to validate the possible advantages of myelin restoration and behavior defects in the FASD mice.
resultsImpaired myelination was observed in the cortex and hippocampus of the male FASD offspring, associated with hyperactivity-like behaviors, whereas the female FASD mice exhibited delayed myelin formation and normal behaviors, indicating a gender-specific manner of FASD pathology. Furthermore, the different myelination deficiency between male and female FASD mice is due to the fact that only the male FASD mice exhibited a failure of oligodendrocyte differentiation. Additionally, FASD exerts an impact on the quantity and differentiation of radial glia cells, which may contribute to the myelination defect. Finally, CF-treated male FASD mice showed myelin regeneration, leading to partial alleviation of behavioral abnormality in the male FASD mice.
conclusionOur data reveal a gender-related deficiency of CNS myelination in the FASD mouse model, suggesting a potential therapy target for FASD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.